SAN FRANCISCO – Use of iRhythm’s Zio cardiac monitoring patch detects asymptomatic atrial fibrillation at a higher rate than routine care, according to a study published recently in JAMA.
Results of the mHealth Screening to Prevent Strokes study, which was conducted at the Scripps Translational Science Institute in partnership with Aetna and Janssen Pharmaceuticals, showed AF was newly diagnosed in 6.7% of patients who were actively monitored by the Zio continuous monitoring patch in a home-based study, as compared to 2.6% in those who received routine care.
“Our study shows an almost threefold improvement in the rate of diagnosis of AF in those actively monitored compared to usual care,” said Dr. Steven Steinhubl, an author of the study. “Diagnosing AF more effectively can enable the initiation of effective therapies and help reduce strokes and death.”
The study also found that 4% of patients in the Zio monitored group were found to have potentially actionable arrhythmias other than AF.
The mHealthSPS study involved 5214 eligible Aetna members who were identified through claims data to have risk factors for AF but had not been previously diagnosed. One-third of individuals were enrolled through a web-based platform to undergo either immediate or delayed active electrocardiograph monitoring at home for up to four weeks with a Zio XT patch monitor.
Using the digital Zio monitoring service by iRhythm enabled the research team to approach a large, geographically diverse population of at-risk individuals and include people who otherwise may have no access to participation in clinical trials because they do not live close to a research center, said Steinhubl.
“This study demonstrates the utility of a digital approach not only to diagnosing asymptomatic AF, but to the clinical research field as a whole,” he said. “We hope that it will set a precedent for future real-world, participant-centric clinical trials that leverage the power of digital medicine technologies.”